A Study of IMR-687 in Healthy Adult Volunteers

NCT02998450 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease
Sickle-Cell; Hb-SC
Sickle Beta 0 Thalassemia

Interventions

DRUG: IMR-687
DRUG: Placebo Oral Capsule

Sponsor

Cardurion Pharmaceuticals, Inc.

Collaborators

[object Object]
[object Object]